MEDI0382 low dose
Sponsors
AstraZeneca, MedImmune LLC
Conditions
Diabetes Mellitus, Type 2Non-alcoholic Fatty Liver Disease (NAFLD)Non-alcoholic Steatohepatitis (NASH)
Phase 2
A Study to Evaluate the Efficacy and Safety of MEDI0382 in the Treatment of Overweight and Obese Subjects With Type 2 Diabetes
CompletedNCT03235050
Start: 2017-08-02End: 2019-06-14Updated: 2020-08-17
A Study to Evaluate Safety and Pharmacodynamic Efficacy of 0382 in Obese Subjects With NAFLD/NASH.
CompletedNCT04019561
Start: 2019-09-23End: 2021-05-06Updated: 2023-01-17